Post-chemotherapy cognitive impairment: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 38: Line 38:
There may be good news on the treatment front, however. Very recently, anecdotal evidence has begun to suggest that certain plasticity-based brain training programs may reduce the effects of post-chemotherapy cognitive impairment. At least one clinical study is underway at [http://www.positscience.com/ Posit Science], other companies are also exploring the field.
There may be good news on the treatment front, however. Very recently, anecdotal evidence has begun to suggest that certain plasticity-based brain training programs may reduce the effects of post-chemotherapy cognitive impairment. At least one clinical study is underway at [http://www.positscience.com/ Posit Science], other companies are also exploring the field.


One study was done of patients 10 years after chemotherapy, which found post-chemotherapy cognitive impairment persists for the affected subgroup.{{fact|date=May 2007}}  No study has found that long-term post-chemotherapy cognitive impairment disappears after 10 years, but that is simply the longest post-chemo period studied to date. Organic nerve damage, one suspected root cause of the condition{{fact|date=May 2007}}, is not generally believed to repair itself.  Research into treatments is ongoing but is at an early stage.
One study was done of patients 10 years after chemotherapy, which found post-chemotherapy cognitive impairment persists for the affected subgroup. No study has found that long-term post-chemotherapy cognitive impairment disappears after 10 years, but that is simply the longest post-chemo period studied to date. Organic nerve damage, one suspected root cause of the condition, is not generally believed to repair itself.  Research into treatments is ongoing but is at an early stage.


The drug Provigil, [[modafinil]], approved for [[narcolepsy]] has been used off-label in trials with people with symptoms of chemobrain. Modafinil is a wakefullness promoting agent  that can improve alertness and concentration.<ref>[http://content.hamptonroads.com/story.cfm?story=133730&ran=181335 Doctors are finding it harder to deny "Chemobrain"]The Virginian-Pilot © October 2, 2007</ref> A University of Rochester study of 68 subjects had significant results. "We knew from previous studies that modafinil does alleviate problems with memory and attention, and were hoping it would do the same for breast-cancer patients experiencing chemo-brain, which it did," related the study's lead author Sadhna Kohli, Ph.D, a research assistant professor at the University of Rochester's James P. Wilmot Cancer Center.<ref>[http://pn.psychiatryonline.org/cgi/content/full/42/15/31  Modafinil Relieves Cognitive Chemotherapy Side Effects]  Psychiatric News, Stephanie Whyche, August 3, 2007 Volume 42 Number 15, page 31</ref>
The drug Provigil, [[modafinil]], approved for [[narcolepsy]] has been used off-label in trials with people with symptoms of chemobrain. Modafinil is a wakefullness promoting agent  that can improve alertness and concentration.<ref>[http://content.hamptonroads.com/story.cfm?story=133730&ran=181335 Doctors are finding it harder to deny "Chemobrain"]The Virginian-Pilot © October 2, 2007</ref> A University of Rochester study of 68 subjects had significant results. "We knew from previous studies that modafinil does alleviate problems with memory and attention, and were hoping it would do the same for breast-cancer patients experiencing chemo-brain, which it did," related the study's lead author Sadhna Kohli, Ph.D, a research assistant professor at the University of Rochester's James P. Wilmot Cancer Center.<ref>[http://pn.psychiatryonline.org/cgi/content/full/42/15/31  Modafinil Relieves Cognitive Chemotherapy Side Effects]  Psychiatric News, Stephanie Whyche, August 3, 2007 Volume 42 Number 15, page 31</ref>

Revision as of 15:55, 18 August 2015

Post-chemotherapy cognitive impairment Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Post-chemotherapy cognitive impairment from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Post-chemotherapy cognitive impairment On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Post-chemotherapy cognitive impairment

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Post-chemotherapy cognitive impairment

CDC on Post-chemotherapy cognitive impairment

Post-chemotherapy cognitive impairment in the news

Blogs on Post-chemotherapy cognitive impairment

Directions to Hospitals Treating Post-chemotherapy cognitive impairment

Risk calculators and risk factors for Post-chemotherapy cognitive impairment

For patient information on this page, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: chemotherapy-induced cognitive dysfunction, chemo brain, chemo fog

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Post-chemotherapy cognitive impairment from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Future or Investigational Therapies

Case Studies

Case#1

Treatment

To date, most people who experience post-chemotherapy cognitive impairment have had to live with it until it (hopefully) dissipates over time. The Mayo Clinic lists several suggestions for coping with post-chemotherapy cognitive impairment, from exercising your body to taking notes that can help guide you through the day.

There may be good news on the treatment front, however. Very recently, anecdotal evidence has begun to suggest that certain plasticity-based brain training programs may reduce the effects of post-chemotherapy cognitive impairment. At least one clinical study is underway at Posit Science, other companies are also exploring the field.

One study was done of patients 10 years after chemotherapy, which found post-chemotherapy cognitive impairment persists for the affected subgroup. No study has found that long-term post-chemotherapy cognitive impairment disappears after 10 years, but that is simply the longest post-chemo period studied to date. Organic nerve damage, one suspected root cause of the condition, is not generally believed to repair itself. Research into treatments is ongoing but is at an early stage.

The drug Provigil, modafinil, approved for narcolepsy has been used off-label in trials with people with symptoms of chemobrain. Modafinil is a wakefullness promoting agent that can improve alertness and concentration.[1] A University of Rochester study of 68 subjects had significant results. "We knew from previous studies that modafinil does alleviate problems with memory and attention, and were hoping it would do the same for breast-cancer patients experiencing chemo-brain, which it did," related the study's lead author Sadhna Kohli, Ph.D, a research assistant professor at the University of Rochester's James P. Wilmot Cancer Center.[2]

References

  1. Doctors are finding it harder to deny "Chemobrain"The Virginian-Pilot © October 2, 2007
  2. Modafinil Relieves Cognitive Chemotherapy Side Effects Psychiatric News, Stephanie Whyche, August 3, 2007 Volume 42 Number 15, page 31
  • Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22:2233-9. PMID 15169812.
  • Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006 Dec 6;98(23):1742-5. PMID 17148777
  • Inagaki M et al. Smaller Regional Volumes of Brain Gray and White Matter Demonstrated in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy. Cancer. DOI 10.1002/cncr.22368. PMID 17131349
  • Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2006 Sep 29; [Epub ahead of print]
  • Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007 Jan 1;109(1):146-56.
  • Posit Science Press Release. “Study on Non-Invasive Therapy for “’Chemobrain.’” 2006 Nov 6.

External links

Template:WH Template:WS